公开(公告)号：US20210155902A1

公开(公告)日：2021-05-27

申请号：US16610624

申请日：2018-05-04

申请人： MEDIZINISCHE HOCHSCHULE HANNOVER

发明人： Nico LACHMANN ,  Mania ACKERMANN ,  Henning KEMPF ,  Robert ZWEIGERDT ,  Thomas MORITZ

IPC分类号： C12N5/0786 ,  C12N5/0787 ,  C12N5/078 ,  A61K35/15 ,  A61K35/18 ,  A61K35/19 ,  A61P31/04 ,  C12P21/00

摘要： The present invention relates to stem-cell derived hematopoietic cells, in particular, myeloid cells, preferably, macrophages, their generation and use. In particular, the invention relates to a method of producing hematopoietic, preferably, myeloid cells, comprising cultivating embryoid bodies, which are, e.g., derivable from pluripotent stem cells such as induced pluripotent stem cells (iPSC), in suspension culture, to produce myeloid cell forming complexes, which are further cultivated in suspension culture to produce myeloid cells such as macrophages. This allows for a scalable and continuous production, e.g., in industry-compatible stirred tank bioreactors. Macrophages, e.g., macrophages produced with this method that have unique characteristics, can be used in pharmaceutical compositions for treatment of patients, e.g., for treatment of infection such as bacterial infection. The invention further provides application systems suitable for spraying, comprising myeloid cells such as macrophages, which can have a reduced size, for use in treatment of patients for treatment of infection, e.g., bacterial infection or wound healing.